Roche used to be a company with strong values, a family spirit. Now Sandra and her cronies fail big and let the -roche- people pay without taking any accountability: Sandra Horning <SandraHorning@gene.com> Nov 14 Dear Colleagues, To prepare for the business challenges ahead and continue to adapt to a dynamic environment, leaders and employees across the company are focused on how we can do the most critical work in more effective, efficient and future oriented ways. I would like to share my reflections on changes occurring in PD as a result of this focus. By now you may have heard about plans to better align Global Clinical Operations (PDG) around the capabilities necessary to support our portfolio. While changes in PDG primarily address reporting lines and organizational structure, they do potentially impact 57 individuals across the function. I know these changes were carefully considered by Jennifer Cook and her leadership team with incorporation of feedback that was intently gathered across PDG. You may also be aware that PD has taken the decision to exit the Roche Innovation Center New York (RICNY) in response to our evolving business needs. As background, PD placed a number of positions at RICNY to support pRED molecule projects located there following the closure of the Nutley, New Jersey site in 2012. Today, however, the majority of pRED projects we support are no longer in RICNY and we therefore felt it appropriate to exit the shared lease with pRED. This decision impacts all 39 PD positions at RICNY. I want to be clear that these decisions do not diminish our commitment to PD’s Basel, South San Francisco, Mississauga, Welwyn, and Shanghai sites, where we will continue to develop the best pipeline in the industry. I also want to acknowledge that the departure of a colleague, especially when unexpected, can be difficult and stressful for everyone. At the same time, we welcome new colleagues, new opportunities, and new ways of working together. It’s important to remember that these decisions are based on the longer term needs of our business, including developing new capabilities. While we all understand the need for ongoing change intellectually, the fact of the matter is that humans don’t like change personally. Looking ahead, I anticipate more changes within PD as we further adjust to the business environment to deliver our pipeline, and we will do our best to help everyone understand these and minimize disruptions. My request of all of you is to remain focused on the important work of doing now what patients need next. Thank you all for everything you do. Warm regards, Sandra
they were mostly useless line managers, the pdg organization is way too bloated. i wouldn't read to much into this. however, cuts will be coming once the biosimilars get picked up by payers
